BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Date and Time: January 6, 2026, 8AM ET Webcast: ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...

Bright Minds Biosciences (DRUG) stock jumps as lead drug BMB-101 succeeds in a mid-stage trial against a severe neurological ...

New research from North Carolina State University pinpoints the areas of the cerebral cortex that are affected in mice with absence epilepsy and shows that transplanting embryonic neural cells into ...

At first, the teacher described her six-year-old student as absentminded, a daydreamer. The boy was having difficulty paying attention in class. As the teacher watched the boy closely, she realized ...

Scientists have discovered a neurological origin for absence seizures -- a type of seizure characterized by very short periods of lost consciousness in which people appear to stare blankly at nothing.